Any feedback?
No. of entries
Information on EC 2.4.1.149 - N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase
for references in articles please use BRENDA:EC2.4.1.149
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree 2 Transferases
2.4 Glycosyltransferases
2.4.1 Hexosyltransferases
2.4.1.149 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase
IUBMB Comments
Acts on β-galactosyl-1,4-N-acetylglucosaminyl termini on glycoproteins, glycolipids, and oligosaccharides.
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
- 2.4.1.149
- glycans
-
muscular
- dystrophy
- glycosyltransferases
- dystroglycanopathies
-
walker-warburg
-
bulb
-
olfactory
- alpha-dystroglycan
- gmppb
- keratan
-
laminin-binding
-
pathfinding
-
glomeruli
-
pomgnt1
- medicine
Reaction Schemes
showSynonyms
b3gnt3, b3gnt1, beta3gnt1, beta3gnt7, beta-1,3-n-acetylglucosaminyltransferase-3, beta3gn-t7, beta1-3 n-acetylglucosaminyltransferase-1, poly-n-acetyllactosamine extension enzyme, udp-glcnac:betagal beta-1,3-n-acetylglucosaminyltransferase 1, beta1,3-n-acetylglucosaminyltransferase-7, more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-acetyllactosaminide beta1-->3-
-
-
-
-
B3gnt1
beta3GnT7
EC 2.4.1.163
-
-
formerly
-
Galbeta1-->4GlcNAc-R beta1-->3 N-acetylglucosaminyltransferase
-
-
-
-
GnT-I
-
-
-
-
i-GlcNAc transferase
-
-
-
-
i-GlcNAcT
-
-
-
-
IGnT
-
-
-
-
N-acetyllactosamine beta(1-3)N-acetylglucosaminyltransferase
-
-
-
-
poly-N-acetyllactosamine extension enzyme
-
-
-
-
UDP-GlcNAc:Galbeta1-->4GlcNAcbeta-Rbeta1-->3-N-acetylglucosaminyltransferase
-
-
-
-
UDP-GlcNAc:Galbeta1-4Glc(NAc) beta-1,3-N-acetylglucosaminyltransferase
-
-
-
-
UDP-GlcNAc:GalR, beta-D-3-N-acetylglucosaminyltransferase
-
-
-
-
uridine diphosphoacetylglucosamine-acetyllactosaminide beta1-->3-acetylglucosaminyltransferase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R = UDP + N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hexosyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
KEGG
MetaCyc
i antigen and I antigen biosynthesis, neolacto-series glycosphingolipids biosynthesis, terminal O-glycans residues modification (via type 2 precursor disaccharide)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetyl-alpha-D-glucosamine:beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R 3-beta N-acetylglucosaminyltransferase (configuration-inverting)
Acts on beta-galactosyl-1,4-N-acetylglucosaminyl termini on glycoproteins, glycolipids, and oligosaccharides.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
85638-39-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Galbeta(1->4)GlcNAcbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 115% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAc
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAc
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo alpha1-acid glycoprotein
?
-
Substrates: sialic acid depleted alpha1-acid glycoprotein, 30% of the activity with neolactotetraosylceramide
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
UDP + N-acetyl-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide
-
Substrates: i.e. neolactotetraosylceramide, GlcNAcT-2, synthesis in vitro of Ii core glycosphingolipids
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP-N-acetyl-D-glucosamine + Fucalpha(1->2)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)[Fucalpha(1->2)]Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
-
Substrates: 32% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta(1-6)(Galbeta(1-4)GlcNAcbeta(1-2))Manalpha(1-6)Manbeta-octyl
?
-
Substrates: regioselectivity of enzyme, favored site of GlcNAc addition is the lower beta1,2-branch over the beta1,6-branch by a 3:1 ratio resulting in a mixture of heptasaccharides
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta-p-nitrophenol
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta-p-nitrophenol
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 48% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GalNAcbeta-O(CH2)2NH2
UDP + GlcNAcbeta(1->3)Galbeta(1->3)GalNAcbeta-O(CH2)2NH2
-
Substrates: 76% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GalNAcbeta-pNP
UDP + GlcNAcbeta(1->3)Galbeta(1->3)GalNAcbeta-pNP
-
Substrates: poor acceptor, 23% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->3)GlcNAcbeta-O(CH2)3N3
-
Substrates: 48% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 101% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 28% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)Glcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)Glcbeta-O(CH2)3N3
-
Substrates: 65% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAc
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAc
-
Substrates: 73% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
-
Substrates: 107% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
-
Substrates: 101% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
-
Substrates: 90% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 57% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->6)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->6)GalNAcalpha-OCH(CH3)CH(NH2)CO2H
-
Substrates: 101% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta(1->6)[GlcNAcbeta(1->4)]Galbeta(1->4)GlcNAcbeta-pNP
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->6)[GlcNAcbeta(1->4)]Galbeta(1->4)GlcNAcbeta-pNP
-
Substrates: 104% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
-
Substrates: 100% activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1->4)[Fucalpha(1->3)]GlcNAcbeta-O(CH2)3N3
UDP + GlcNAcbeta(1->3)Galbeta(1->4)[Fucalpha(1->3)]GlcNAcbeta-O(CH2)3N3
-
Substrates: 26% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,4(SO3-,6)-GlcNAcbeta1,3(SO3-,6)-Galbeta1,4(SO3-,6)-GlcNAc
UDP + GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAcbeta1,3(SO3-,6)-Galbeta1,4(SO3-,6)-GlcNAc
-
Substrates: i.e. L2L4, 72% activity compared to L2L2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc
UDP + GlcNAcbeta1,3-Galbeta1,4(SO3-,6)GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc
-
Substrates: i.e. L2L2, a 6-O-sulfated keratan sulfate, best substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc
UDP + GlcNAcbeta1,3-Galbeta1,4(SO3-,6)GlcNAcbeta1,3Galbeta1,4(SO3-,6)-GlcNAc
-
Substrates: i.e. L2L2, a 6-O-sulfated keratan sulfate, best substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
UDP + GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: -
Products: mixture of the pentasaccharide product, 27 mol%, and the unreacted tetrasaccharide, 73 mol%
Products: mixture of the pentasaccharide product, 27 mol%, and the unreacted tetrasaccharide, 73 mol%
?
UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta1-OMe
UDP + GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta1-OMe
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta1-OMe
UDP + GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta1-OMe
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta1-OR
UDP + GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta1-OR
-
Substrates: i.e. N,N-diacetyllactosediamine-OR
Products: only 12.5% of the substrate is converted into the product, which is unusually resistant towards jackbean beta-N-acetylhexosaminidase
Products: only 12.5% of the substrate is converted into the product, which is unusually resistant towards jackbean beta-N-acetylhexosaminidase
?
UDP-N-acetyl-D-glucosamine + glycolipid
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + keratan sulfate
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + lactosylceramide
?
-
Substrates: 15% of the activity with neolactotetraosylceramide
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + O-glycan
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: poly-N-acetyllactosamine is biosynthesized by the alternating addition of N-acetyl-D-glucosamine by UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase and Gal by UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein
UDP + N-acetylglucosaminylated asialo-alpha1-acid glycoprotein
UDP-N-acetylglucosamine + asialo-fetuin
UDP + N-acetylglucosaminylated asialo-fetuin
-
Substrates: much less effective than asialo-alpha1-acid glycoprotein, transfer of GlcNAc to a terminal Gal in a beta1,3-linkage
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-transferrin
UDP + N-acetylglucosaminylated asialo-transferrin
-
Substrates: much less effective than asialo-alpha1-acid glycoprotein, transfer of GlcNAc to a terminal Gal in a beta1,3-linkage
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactoneotetraosylceramide
?
-
Substrates: lactoneotetraosylceramide from bovine erythrocytes, higher rate than with lactonorhexaosylceramide, efficiency decreases with growing acceptor chain length
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactonorhexaosylceramide
?
-
Substrates: lactonorhexaosylceramide from bovine erythrocytes, lower rate than with lactoneotetraosylceramide, efficiency decreases with growing acceptor chain length
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactosylceramide
?
-
Substrates: lactosylceramide from human erythrocytes
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactotetraosylceramide
?
-
Substrates: lactotetraosylceramide from human meconium, poor substrate
Products: -
Products: -
?
UDP-N-acetylglucosamine + porcine submaxillary asialo-afuco-mucin
UDP + N-acetylglucosaminylated porcine submaxillary asialo-afuco-mucin
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
Substrates: iGnT has a unique characteristic in binding to acceptor substrates, preferentially adding poly-N-acetyllactosamine to membrane glycoproteins
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: involved in the biosynthesis of blood group precursors, enzyme might control the biosynthesis of the linear carbohydrate chain by adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R structure present on oligosaccharides, glycosylceramides and glycoproteins
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
Substrates: enzyme is essential for the formation of poly-N-acetyllactosamines and the i-antigen, responsible for the formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and poly-N-acetyllactosamine extension
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: B3GNT1 displays an in vitro preference for the GlcNAcbeta1->2Man branch
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: acts on beta-galactosyl-1,4-N-acetylglucosaminyl termini on asialo-alpha1-acid glycoproteins and other glycoproteins and oligosaccharides, GlcNAc residues are introduced to position C-3 of the terminal galactose of the glycoprotein
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: highly specific for acceptor oligosaccharides and glycoproteins carrying a terminal Galbeta(1-4)GlcNAcbeta1-R unit, catalyzes the formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta-R sequence, Galbeta(1-4)GlcNAcbeta(1-2)(Galbeta(1-4)GlcNAcbeta(1-6))Man pentasaccharide in the acceptor structure is a requirement for optimal activity, branch specificity, branches of this pentasaccharide structure, when contained in tri- and tetraantennary oligosaccharides, are highly preferred over other branches for attachment of the 1st and 2nd mol of GlcNAc into the acceptor molecule, enzyme also shows activity towards oligosaccharides related to blood group I- and i-active polylactosaminoglycans
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: might function in the biosynthesis of cell surface polylactosaminoglycans on Novikoff cells and blood group i antigenic structures, enzyme controls the synthesis of linear chain types by adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R primer structure present on glycoprotein or glycolipid yielding a GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: enzyme functions in both the initiation and elongation of linear i-active polylactosaminoglycan chains of N-glycoproteins and possibly other glycoconjugates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: i.e. lacto-N-neotetraose, 117% of activity with N-acetyllactosamine
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-glycan
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-glycan
?
-
Substrates: polylactosamine extension occurs on both beta1,2- and beta1,6-branches of complex N-type glycans
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: involved in the initiation and extension of poly-N-acetyllactosamine biosynthesis, may act as a key enzyme
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: synthesis of N-acetyllactosamine repeats in Asn-linked oligosaccharides is enhanced by an increase of enzyme
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: enzyme is capable of elongation of polylactosamine i-chains
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: poly-N-acetyllactosamine biosynthesis, polylactosamine extension occurs on both beta1,2- and beta1,6-branches of complex N-type glycans
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: biosynthesis of poly-N-acetyllactosamine chains on N-linked oligosaccharides, catalyzes a rate-limiting reaction in the expression of poly-N-acetyllactosamine chains, especially in pheochromocytoma cells
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein
UDP + N-acetylglucosaminylated asialo-alpha1-acid glycoprotein
-
Substrates: best acceptor among the glycoproteins that contain Galbeta(1-4)GlcNAc
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein
UDP + N-acetylglucosaminylated asialo-alpha1-acid glycoprotein
Substrates: -
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein
UDP + N-acetylglucosaminylated asialo-alpha1-acid glycoprotein
-
Substrates: GlcNAc residues are introduced to position C-3 of the terminal galactose of the glycoprotein, relative high activity towards asialo-alpha1-acid glycoprotein in Novikoff ascites tumor cells
Products: -
Products: -
?
UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein
UDP + N-acetylglucosaminylated asialo-alpha1-acid glycoprotein
-
Substrates: much more effective than asialo-transferrin and asialo-fetuin, asialo-alpha1-acid glycoprotein from human plasma Cohn fraction V, transfer of GlcNAc to a terminal Gal in a beta1,3-linkage
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactose
UDP + GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: transfer of one GlcNAc to position C-3 of the terminal Gal residue of lactose or N-acetyllactosamine in the beta linkage, 51% of activity with N-acetyllactosamine
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactose
UDP + GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: less physiological acceptor than N-acetyllactosamine
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactose
UDP + GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: less effective acceptor than N-acetyllactosamine
Products: -
Products: -
?
UDP-N-acetylglucosamine + lactose
UDP + GlcNAcbeta(1-3)Galbeta(1-4)Glc
-
Substrates: 70% of activity with N-acetyllactosamine
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: transfer of one GlcNAc to position C-3 of the terminal Gal residue of lactose or N-acetyllactosamine in the beta linkage
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: more physiological acceptor than lactose
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: more effective acceptor than lactose
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetylglucosamine + N-acetyllactosamine
UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc
-
Substrates: more effective acceptor than lactose
Products: -
Products: -
?
UDP-N-acetylglucosamine + porcine submaxillary asialo-afuco-mucin
UDP + N-acetylglucosaminylated porcine submaxillary asialo-afuco-mucin
-
Substrates: very poor substrate
Products: -
Products: -
?
UDP-N-acetylglucosamine + porcine submaxillary asialo-afuco-mucin
UDP + N-acetylglucosaminylated porcine submaxillary asialo-afuco-mucin
-
Substrates: poor acceptor, Galbeta(1-3)GalNAc as terminal acceptor structure
Products: -
Products: -
?
additional information
?
-
-
Substrates: terminal Galbeta(1-4)Glc(NAc) sequences, i.e. type II chains, are preferred substrates, no substrates: terminal Galbeta(1-3)GlcNAc sequences, i.e. type I chains, Lewis X trisaccharides, i.e. Galbeta(1-4)(Fucalpha(1-3))GlcNAc, monosaccharides, e.g. galactose, asialo-bovine submaxillary mucin that contains GalNAcalpha1-Ser/Thr and Galbeta(1-3)GalNAcalpha1-Ser/Thr
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme shows no activity on a terminal Gal with Neu5Acalpha(2->6) substitution. Terminal galactose with alpha-linkage, Galalpha(1->3)Gal or Galalpha(1->4)Gal is not an acceptor substrate for the enzyme
Products: -
Products: -
?
additional information
?
-
-
Substrates: no acceptors: melibiose, gentiobiose, galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: transfer of GlcNAc occurs mainly to type 2 chain nonfucosylated structures, elongation of type 1 chain structure Lc4 is also detectable, no transfer to any fucosylated derivative of either type 1 or 2 chains, transfer of GlcNAc to a terminal Gal residue on a lacto-series core chain
Products: -
Products: -
?
additional information
?
-
Substrates: no acceptor: Galbeta(1-3)GlcNAcbeta(1-3)Galbeta(1-4)Glc
Products: -
Products: -
?
additional information
?
-
-
Substrates: biosynthesis of lacto-series core chains, enzyme is activated in association with oncogenesis in colonic epithelia
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme together with N-acetyllactosamine synthase, EC 2.4.1.90, catalyzes formation of linear glycans containing alternating beta-3-O-substituted residues of D-galactose and beta-4-O-substituted residues of N-acetyl-D-glucosamine, structures are present among others in glycosphingolipids or H-II type, polyglycosylceramides and polyglycosylpeptides, e.g. erythroglycan
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is in volved in biosynthesis of keratan sulfate, overview, enzyme is an anti-migration factor for a lung cancer cell line
Products: -
Products: -
?
additional information
?
-
-
Substrates: substrate specificity, enzyme acts efficiently on keratan sulfate-related glycans, while lacto-N-tetraose and lacto-N-neo-tetraose are poor substrates, overview, product analysis
Products: -
Products: -
?
additional information
?
-
Substrates: transglycosylation reaction follows a sequential mechanism
Products: -
Products: -
-
additional information
?
-
Substrates: transglycosylation reaction follows a sequential mechanism. Kd values of UDP-GlcNAc and UDP are around 0.14 and 0.26 mM, respectively
Products: -
Products: -
-
additional information
?
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
additional information
?
-
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
additional information
?
-
-
Substrates: biosynthesis of Ii core glycosphingolipids
Products: -
Products: -
?
additional information
?
-
-
Substrates: B3gnt1 null females are fertile, the B3gnt1 null males are not able to sire litters at the expected rate when mated to either wild type or B3gnt1-null females
Products: -
Products: -
?
additional information
?
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
additional information
?
-
-
Substrates: asialo-serum glycoproteins are much more effective than O-glycoproteins as acceptors, overview over oligosaccharide substrates
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP-N-acetyl-D-glucosamine + glycolipid
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + keratan sulfate
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + O-glycan
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: involved in the biosynthesis of blood group precursors, enzyme might control the biosynthesis of the linear carbohydrate chain by adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R structure present on oligosaccharides, glycosylceramides and glycoproteins
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
Substrates: enzyme is essential for the formation of poly-N-acetyllactosamines and the i-antigen, responsible for the formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and poly-N-acetyllactosamine extension
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: might function in the biosynthesis of cell surface polylactosaminoglycans on Novikoff cells and blood group i antigenic structures, enzyme controls the synthesis of linear chain types by adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R primer structure present on glycoprotein or glycolipid yielding a GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R
-
Substrates: enzyme functions in both the initiation and elongation of linear i-active polylactosaminoglycan chains of N-glycoproteins and possibly other glycoconjugates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-glycan
?
-
Substrates: physiological acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-glycan
?
-
Substrates: polylactosamine extension occurs on both beta1,2- and beta1,6-branches of complex N-type glycans
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: involved in the initiation and extension of poly-N-acetyllactosamine biosynthesis, may act as a key enzyme
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: synthesis of N-acetyllactosamine repeats in Asn-linked oligosaccharides is enhanced by an increase of enzyme
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: enzyme is capable of elongation of polylactosamine i-chains
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: poly-N-acetyllactosamine biosynthesis, polylactosamine extension occurs on both beta1,2- and beta1,6-branches of complex N-type glycans
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine
?
-
Substrates: biosynthesis of poly-N-acetyllactosamine chains on N-linked oligosaccharides, catalyzes a rate-limiting reaction in the expression of poly-N-acetyllactosamine chains, especially in pheochromocytoma cells
Products: -
Products: -
?
additional information
?
-
-
Substrates: biosynthesis of lacto-series core chains, enzyme is activated in association with oncogenesis in colonic epithelia
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme together with N-acetyllactosamine synthase, EC 2.4.1.90, catalyzes formation of linear glycans containing alternating beta-3-O-substituted residues of D-galactose and beta-4-O-substituted residues of N-acetyl-D-glucosamine, structures are present among others in glycosphingolipids or H-II type, polyglycosylceramides and polyglycosylpeptides, e.g. erythroglycan
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is in volved in biosynthesis of keratan sulfate, overview, enzyme is an anti-migration factor for a lung cancer cell line
Products: -
Products: -
?
additional information
?
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
additional information
?
-
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
additional information
?
-
-
Substrates: biosynthesis of Ii core glycosphingolipids
Products: -
Products: -
?
additional information
?
-
-
Substrates: B3gnt1 null females are fertile, the B3gnt1 null males are not able to sire litters at the expected rate when mated to either wild type or B3gnt1-null females
Products: -
Products: -
?
additional information
?
-
Substrates: beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
Co2+
Mg2+
Mn2+
additional information
Mn2+
-
optimum concentration: 2-15 mM, cooperative activating effects by combination of Mn2+ at a low concentration and Mg2+ or Ca2+
Mn2+
-
requirement, Km: 1.25 mM, Mn2+ cannot be replaced by Mg2+, Zn2+, Cu2+ or Cd2+
additional information
-
enzyme possesses 2 distinct metal binding sites, not activated by Ca2+, Mg2+, Zn2+, Fe2+, Cu2+, Ni2+, K+, Na+
additional information
-
absolute requirement for divalent cations, not stimulated by Mg2+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
1-[(2R)-3,3-dimethylbutan-2-yl]-6-(5-methyl-5-phenyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-(morpholine-4-carbonyl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(1H-indol-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(2,3-dimethyl-1H-indol-5-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(imidazo[1,2-a]pyridin-6-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-methyl-5-oxo-2-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-5-oxo-2-(pyridin-3-yl)-2-(4H-1,2,4-triazol-3-yl)-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-2-oxo-5-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydrofuran-3-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[2-(trifluoromethyl)pyrimidin-5-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[5-(trifluoromethyl)pyridin-2-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(5-methylpyridin-2-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(5-methylpyrimidin-2-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(6-methylpyridin-3-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
3-(2-methylpropyl)-2-oxo-2,3-dihydro-1H-1,3-benzimidazole-5-carboxylic acid
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazole-5-carboxylic acid
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxylic acid
-
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-(propan-2-yl)-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-phenyl-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-[(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-[(1S)-1-[5-(trifluoromethyl)pyridin-2-yl]ethyl]-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-N-(2,3-dimethyl-1H-indol-6-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-N-[(1S)-1-(2-methylpyrimidin-5-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
3-[(2R)-3,3-dimethylbutan-2-yl]-N-[(1S)-1-(5-methylpyridin-2-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
6-[(2R)-2-(2-chloropyrimidin-5-yl)-5-oxo-2-(pyridin-2-yl)-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(2R)-2-(5-chloropyridin-2-yl)-2-(6-chloropyridin-3-yl)-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(2S)-2-benzyl-5-oxo-2-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(5R)-5-(5-chloropyridin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(5S)-5-(5-chloropyridin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
6-[(5S)-5-(5-chloropyrimidin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
N-[(1R)-1-(4-chlorophenyl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(2-chloropyrimidin-5-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(4-chlorophenyl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(5-bromopyridin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(5-chloropyrazin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(5-chloropyridin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(1S)-1-(5-chloropyrimidin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[(4-chlorophenyl)methyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
N-[2-(4-chlorophenyl)propan-2-yl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
-
additional information
-
nerve growth factor stimulated PC-12 cells with reduced GnT-i activity compared to unstimulated cells, no effect in PC-12D cells
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
detergent
-
activates, reaction rate is optimal at detergent:protein ratio of 1.6 in Triton CF-54 or X-100, 1:3 in Nonidet P-40
-
Triton CF-54
-
activates solubilized enzyme, activity is optimal when assayed in the presence of a final concentration of 0.3%
additional information
-
CDPcholine stimulates by protecting UDP-GlcNAc from hydrolysis by endogenous enzymes
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma.
Adenocarcinoma of Lung
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
Carcinogenesis
B3GNT3, a Direct Target of miR-149-5p, Promotes Lung Cancer Development and Indicates Poor Prognosis of Lung Cancer.
Carcinoma
B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Endometrial Neoplasms
B3GNT3 acts as a carcinogenic factor in endometrial cancer via facilitating cell growth, invasion and migration through regulating RhoA/RAC1 pathway-associated markers.
Infections
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Lung Neoplasms
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Lung Neoplasms
B3GNT3, a Direct Target of miR-149-5p, Promotes Lung Cancer Development and Indicates Poor Prognosis of Lung Cancer.
Lung Neoplasms
beta1,3-N-Acetylglucosaminyltransferase-7 (beta3Gn-T7) acts efficiently on keratan sulfate-related glycans.
Lymphatic Metastasis
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Lymphatic Metastasis
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Muscular Dystrophies
B4GAT1 is the priming enzyme for the LARGE-dependent functional glycosylation of ?-dystroglycan.
Muscular Dystrophies
Integrative data mining highlights candidate genes for monogenic myopathies.
Neoplasm Metastasis
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Neoplasm Metastasis
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Neoplasm Metastasis
B3GNT3, a Direct Target of miR-149-5p, Promotes Lung Cancer Development and Indicates Poor Prognosis of Lung Cancer.
Neoplasms
B3GNT3 acts as a carcinogenic factor in endometrial cancer via facilitating cell growth, invasion and migration through regulating RhoA/RAC1 pathway-associated markers.
Neoplasms
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Neoplasms
B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.
Neoplasms
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
Neoplasms
B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer.
Neoplasms
B3GNT3, a Direct Target of miR-149-5p, Promotes Lung Cancer Development and Indicates Poor Prognosis of Lung Cancer.
Neoplasms
B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma.
Neoplasms
Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Neoplasms
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
Neoplasms
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Neoplasms
Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.
Neuroblastoma
B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.
Pancreatic Neoplasms
B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer.
Pancreatic Neoplasms
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Prostatic Neoplasms
Missense mutations in ?-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
Uterine Cervical Neoplasms
B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Walker-Warburg Syndrome
A truncating mutation in B3GNT1 causes severe Walker-Warburg syndrome.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.36
Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc
-
recombinant enzyme, pH 7.2, 37°C
1.445
UDP-N-acetyl-D-glucosamine
-
using Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H as acceptor, in cacodylate buffer (100 mM, pH 7.5), at 37°C
1.487
UDP-N-acetyl-D-glucosamine
-
using Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 as acceptor, in cacodylate buffer (100 mM, pH 7.5), at 37°C
2.082
UDP-N-acetyl-D-glucosamine
-
using Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H as acceptor, in cacodylate buffer (100 mM, pH 7.5), at 37°C
15.97
UDP-N-acetyl-D-glucosamine
-
using Galbeta(1->3)GlcNAcbeta-O(CH2)3N3 as acceptor, in cacodylate buffer (100 mM, pH 7.5), at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0009
1-[(2R)-3,3-dimethylbutan-2-yl]-6-(5-methyl-5-phenyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0266
1-[(2R)-3,3-dimethylbutan-2-yl]-6-(morpholine-4-carbonyl)-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000053 - 0.000055
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(1H-indol-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
0.00101
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(2,3-dimethyl-1H-indol-5-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.00037
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(imidazo[1,2-a]pyridin-6-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000024
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-methyl-5-oxo-2-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000026
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-5-oxo-2-(pyridin-3-yl)-2-(4H-1,2,4-triazol-3-yl)-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000028
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-2-oxo-5-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydrofuran-3-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0006
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-phenyl-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000009
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[2-(trifluoromethyl)pyrimidin-5-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.00003
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[5-(trifluoromethyl)pyridin-2-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000008
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-4-oxo-5-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000096
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(5-methylpyridin-2-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000024
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(5-methylpyrimidin-2-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000029
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(5S)-5-methyl-5-(6-methylpyridin-3-yl)-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0091
3-(2-methylpropyl)-2-oxo-2,3-dihydro-1H-1,3-benzimidazole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.00026
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-1,3-benzimidazole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.122
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0029
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-(propan-2-yl)-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00082
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-phenyl-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00007
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-[(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00023
3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-N-[(1S)-1-[5-(trifluoromethyl)pyridin-2-yl]ethyl]-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00006 - 0.165
3-[(2R)-3,3-dimethylbutan-2-yl]-N-(2,3-dimethyl-1H-indol-6-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
0.00012
3-[(2R)-3,3-dimethylbutan-2-yl]-N-[(1S)-1-(2-methylpyrimidin-5-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000093
3-[(2R)-3,3-dimethylbutan-2-yl]-N-[(1S)-1-(5-methylpyridin-2-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000039
6-[(2R)-2-(2-chloropyrimidin-5-yl)-5-oxo-2-(pyridin-2-yl)-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0002
6-[(2R)-2-(5-chloropyridin-2-yl)-2-(6-chloropyridin-3-yl)-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000069
6-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000013
6-[(2S)-2-benzyl-5-oxo-2-[2-(trifluoromethyl)pyrimidin-5-yl]-2,5-dihydro-1H-imidazol-4-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.00051
6-[(5R)-5-(5-chloropyridin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000066
6-[(5S)-5-(5-chloropyridin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000082
6-[(5S)-5-(5-chloropyrimidin-2-yl)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-1-[(2R)-3,3-dimethylbutan-2-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.00272
N-[(1R)-1-(4-chlorophenyl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000076
N-[(1S)-1-(2-chloropyrimidin-5-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00029
N-[(1S)-1-(4-chlorophenyl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0001 - 0.169
N-[(1S)-1-(5-bromopyridin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
0.00089
N-[(1S)-1-(5-chloropyrazin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00023
N-[(1S)-1-(5-chloropyridin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00043
N-[(1S)-1-(5-chloropyrimidin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00061
N-[(4-chlorophenyl)methyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00084
N-[2-(4-chlorophenyl)propan-2-yl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000053
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(1H-indol-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000055
1-[(2R)-3,3-dimethylbutan-2-yl]-6-[(2S)-2-(1H-indol-2-yl)-2-methyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Homo sapiens
pH and temperature not specified in the publication
0.00006
3-[(2R)-3,3-dimethylbutan-2-yl]-N-(2,3-dimethyl-1H-indol-6-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.165
3-[(2R)-3,3-dimethylbutan-2-yl]-N-(2,3-dimethyl-1H-indol-6-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0001
N-[(1S)-1-(5-bromopyridin-2-yl)ethyl]-3-[(2R)-3,3-dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
breast cancer cell line, higher expression of beta3GnT7 in cancer cell lines with low degrees of invasiveness
brenda
KLN205-MUC1, lung cancer cell line, higher expression of beta3GnT7 in cancer cell lines with low degrees of invasiveness
brenda
NSCLC, quantitative real-time PCR enzyme expression analysis
brenda
-
pheochromacytoma cells, nerve growth factor stimulated cells with reduced GnT-i activity compared to unstimulated cells
brenda
-
new subline of pheochromacytoma cells PC-12, low GnT-i activity
brenda
B3GNT3 is highly expressed in endometrial cancer tissues compared to normal tissues. High B3GNT3 expression presents a worse overall survival in endometrial cancer patients as compared with low B3GNT3 expression group
brenda
additional information
beta3GnT7 is most strongly expressed in the placenta and colon
brenda
-
beta3GnT7 is most strongly expressed in the placenta and colon
-
brenda
beta3GnT7 is most strongly expressed in the placenta at the later stages of gestation and in colon
brenda
-
beta3GnT7 is most strongly expressed in the placenta at the later stages of gestation and in colon
-
brenda
additional information
-
enzyme is undetectable in normal colonic epithelial cells, but is greatly enhanced both during fetal development and in colonic adenocarcinomas
brenda
additional information
enzyme is expressed ubiquitously in various adult tissues
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
stem region and large catalytic domain reside presumably in the Golgi lumen
brenda
-
B3GNT1 and B4GALT1 colocalize and interact with each other in the trans-Golgi
brenda
type II membrane protein topology, longest transmembrane domain among glycosyltransferases cloned so far
brenda
Highest Expressing Human Cell Lines
Cell Line LinksPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug target
B3GNT3 acts as an oncogene that promotes endometrial cancer cell growth, invasion and migration possibly through regulating the RhoA/RAC1 signaling pathway-related markers, suggesting that B3GNT3 may be a candidate biomarker for EC therapeutic intervention
malfunction
B3GNT2 is the major poly-N-acetyl-lactosamine synthase, and deletion of its coding gene dramatically reduces the cell surface poly-N-acetyl-lactosamine and leads to hypersensitive and hyperresponsive immunocytes
physiological function
physiological function
-
beta3GnT1 is required for laminin-binding glycan synthesis through formation of a complex with LARGE, thus regulating the function of LARGE
physiological function
in the 176 non-small cell lung cancer (NSCLC) cases, a high B3GNT3 expression level is positively correlated with lymph node metastasis and advanced TNM (tumor, node, metastasis) stage. Kaplan-Meier analysis indicates that patients with high B3GNT3 expression have significantly lower disease-free survival and overall survival than those with low B3GNT3 expression. B3GNT3 expression is an independent prognostic factor
physiological function
B3GNT3 acts as a carcinogenic factor in endometrial cancer via facilitating cell growth, invasion and migration through regulating RhoA/RAC1 pathway-associated markers
physiological function
the enzyme is involved in the biosynthesis of poly-N-acetyl-lactosamine chains. Poly-N-acetyl-lactosamine is involved in the immune system in many ways. Its long chain suppresses excessive immune responses
physiological function
deletion of B3GNT2 in Jurkat cells results in a significant decrease in polylactosamine levels relative to wild-type
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). B3GN4_MOUSE
350
1
39873
Swiss-Prot
Secretory Pathway (Reliability: 1)
B3GN4_HUMAN
378
0
42310
Swiss-Prot
other Location (Reliability: 2)
A0A6P6PCH3_CARAU
520
0
58171
TrEMBL
other Location (Reliability: 4)
A0AAD8YY79_9TELE
1338
0
148064
TrEMBL
other Location (Reliability: 2)
B3GN7_HUMAN
401
0
45987
Swiss-Prot
Secretory Pathway (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
47125
x * 47125, calculated from the amino acid sequence, mature N-glycosylated iGnT: may be approximately 53 kDa
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
x * 47125, calculated from the amino acid sequence, mature N-glycosylated iGnT: may be approximately 53 kDa
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging-drop vapor diffusion method, crystal structures of B3GNT2 are determined in the unliganded, donor substrate-bound, acceptor substrate-bound, and product(s) bound states at resolutions ranging from 1.85 to 2.35 A
structures of the unliganded, donor substrate-bound, acceptor substrate-bound, and product(s)-bound states at resolutions ranging from 1.85 to 2.35 A
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D245A
residue involved in substrate binding, significantly reduced enzyme activity
D247A
residue involved in metal binding, significantly reduced enzyme activity
D332A
residue involved in substrate binding, significantly reduced enzyme activity
D333N
mutation of active site base, significantly reduced enzyme activity
H376E
residue involved in metal binding, significantly reduced enzyme activity
H376L
residue involved in metal binding, significantly reduced enzyme activity
H376Q
residue involved in metal binding, significantly reduced enzyme activity
K149A
residue involved in substrate binding, significantly reduced enzyme activity
Y289F
residue involved in substrate binding, significantly reduced enzyme activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
cDNA from melanoma and colonic cancer cells is cloned and overexpressed in human Burkitt lymphoma Namalwa KJM-1 cells overexpressing the i-antigen, nucleotide and amino acid sequence of the 415-amino acids protein, cDNA fragment encoding the stem region plus putative catalytic domain of iGnT fused to protein A is expressed in COS-1 cells
cDNA from placenta encoding beta3GnT7 is cloned and partially characterized, open reading frame encodes a 397-amino acids protein
human ortholog to mouse enzyme beta3GnT7 has the chromosomal locus 2q37.1
plasmid cDNA encoding the catalytic domain of i-GlcNAcT, amino acids 53-415, is expressed in COS-1 cells
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
B3GNT3 is highly expressed in endometrial cancer tissues compared to normal tissues
forced expression of beta3GnT1 in aggressive cancer cells restores the laminin-binding glycans and decreased tumor formation
-
the decrease of laminin-binding glycans and consequent increased cell migration are associated with the decreased expression of beta3-N-acetylglucosaminyltransferase-1
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
high expression of B3GNT3 is associated with unfavourable disease-free survival and overall survival in NSCLC patients, suggesting that B3GNT3 might be a potential prognostic biomarker for non-small cell lung cancer (NSCLC). B3GNT3 expression is an independent prognostic factor
medicine
medicine
enzyme may be used as diagnostic marker of human cancer or as target molecule for the development of a new therapy
medicine
-
enzyme may be used as diagnostic marker of human cancer or as target molecule for the development of a new therapy
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Van den Eijnden, D.H.; Winterwerp, H.; Smeeman, P.; Schiphorst, W.E.C.M.
Novikoff ascites tumor cells contain N-acetyllactosaminide beta 1-3 and beta 1-6 N-acetylglucosaminyltransferase activity
J. Biol. Chem.
258
3435-3437
1983
Rattus norvegicus
brenda
Zielenski, J.; Koscielak, J.
The occurrence of two novel N-acetylglucosaminyltransferase activities in human serum
FEBS Lett.
158
164-168
1983
Homo sapiens
brenda
Hosomi, O.; Takeya, A.; Kogure, T.
Human serum contains N-acetyllactosamine: beta 1-3 N-acetylglucosaminyltransferase activity
J. Biochem.
95
1655-1659
1984
Homo sapiens
brenda
Holmes, E.H.
Characterization of a beta 1-->3-N-acetylglucosaminyltransferase associated with synthesis of type 1 and type 2 lacto-series tumor-associated antigens from the human colonic adenocarcinoma cell line SW403
Arch. Biochem. Biophys.
260
461-468
1988
Homo sapiens
brenda
van den Eijnden, D.H.; Koenderman, A.H.L.; Schiphorst, W.E.C.M.
Biosynthesis of blood group i-active polylactosaminoglycans. Partial purification and properties of an UDP-GlcNAc:N-acetyllactosaminide beta 1-->3-N-acetylglucosaminyltransferase from Novikoff tumor cell ascites fluid
J. Biol. Chem.
263
12461-12471
1988
Rattus norvegicus
brenda
Kawashima, H.; Yamamoto, K.; Osawa, T.; Irimura, T.
Purification and characterization of UDP-GlcNAc:Galbeta 1-4Glc(NAc)beta-1,3-N-acetylglucosaminyltransferase (poly-N-acetyllactosamine extension enzyme) from calf serum
J. Biol. Chem.
268
27118-27126
1993
Bos taurus
brenda
McAuliffe, J.C.; Ujita, M.; Fukuda, M.; Hindsgaul, O.
Synthesis of selectively radiolabeled hexasaccharides for the determination of enzymatic regioselectivity
Glycoconjugate J.
16
767-772
1999
Homo sapiens
brenda
Fukuzumi, M.; Maruyama, S.; Sano, M.; Fukui, S.
Comparison of the expression of cell surface poly-N-acetyllactosamine-type oligosaccharides in PC12 cells with those in its variant PC12D
Glycobiology
11
481-494
2001
Rattus norvegicus
brenda
Kataoka, K.; Huh, N.h.
A novel beta1,3-N-acetylglucosaminyltransferase involved in invasion of cancer cells as assayed in vitro
Biochem. Biophys. Res. Commun.
294
843-848
2002
Homo sapiens (Q8NFL0), Homo sapiens, Mus musculus (Q8K0J2), Mus musculus, Mus musculus beta3GnT7 (Q8K0J2)
brenda
Sasaki, K.; Kurata-Miura, K.; Ujita, M.; Angata, K.; Nakagawa, S.; Sekine, S.; Nishi, T.; Fukuda, M.
Expression cloning of cDNA encoding a human beta-1,3-N-acetylglucosaminyltransferase that is essential for poly-N-acetyllactosamine synthesis
Proc. Natl. Acad. Sci. USA
94
14294-14299
1997
Homo sapiens (O43505)
brenda
Salo, H.; Aitio, O.; Ilves, K.; Bencomo, E.; Toivonen, S.; Penttil, L.; Niemel, R.; Salminen, H.; Grabenhorst, E.; Renkonen, R.; Renkonen, O.
Several polylactosamine-modifying glycosyltransferases also use internal GalNAcbeta1-4GlcNAc units of synthetic saccharides as acceptors
Glycobiology
12
217-228
2002
Homo sapiens
brenda
Hummel, M.; Hedrich, H.C.; Hasilik, A.
Elongation of N-acetyllactosamine repeats in diantennary oligosaccharides
Eur. J. Biochem.
245
428-433
1997
Cricetulus griseus
brenda
Basu, M.; Basu, S.
Biosynthesis in vitro of Ii core glycosphingolipids from neolactotetraosylceramide by beta1-3- and beta1-6-N-acetylglucosaminyltransferases from mouse T-lymphoma
J. Biol. Chem.
259
12557-12562
1984
Mus musculus
brenda
Seko, A.; Yamashita, K.
beta1,3-N-Acetylglucosaminyltransferase-7 (beta3Gn-T7) acts efficiently on keratan sulfate-related glycans
FEBS Lett.
556
216-220
2004
Homo sapiens
brenda
Biellmann, F.; Henion, T.R.; Burki, K.; Hennet, T.
Impaired sexual behavior in male mice deficient for the beta 1-3 N-acetylglucosaminyltransferase-I gene
Mol. Reprod. Dev.
75
699-706
2008
Mus musculus
brenda
Lee, P.L.; Kohler, J.J.; Pfeffer, S.R.
Association of beta-1,3-N-acetylglucosaminyltransferase 1 and beta-1,4-galactosyltransferase 1, trans-Golgi enzymes involved in coupled poly-N-acetyllactosamine synthesis
Glycobiology
19
655-664
2009
Homo sapiens
brenda
Bao, X.; Kobayashi, M.; Hatakeyama, S.; Angata, K.; Gullberg, D.; Nakayama, J.; Fukuda, M.; Fukuda, M.
Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase
Proc. Natl. Acad. Sci. USA
106
12109-12114
2009
Homo sapiens
brenda
Peng, W.; Pranskevich, J.; Nycholat, C.; Gilbert, M.; Wakarchuk, W.; Paulson, J.C.; Razi, N.
Helicobacter pylori beta1,3-N-acetylglucosaminyltransferase for versatile synthesis of type 1 and type 2 poly-LacNAcs on N-linked, O-linked and I-antigen glycans
Glycobiology
22
1453-1464
2012
Helicobacter pylori
brenda
Gao, L.; Zhang, H.; Zhang, B.; Zhu, J.; Chen, C.; Liu, W.
B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer
J. Clin. Pathol.
71
642-647
2018
Homo sapiens (Q9Y2A9), Homo sapiens
brenda
Wang, J.S.; Ruan, F.; Guo, L.Z.; Wang, F.G.; Wang, F.L.; An, H.M.
B3GNT3 acts as a carcinogenic factor in endometrial cancer via facilitating cell growth, invasion and migration through regulating RhoA/RAC1 pathway-associated markers
Genes Genomics
43
447-457
2021
Homo sapiens (Q9Y2A9)
brenda
Hao, Y.; Crequer-Grandhomme, A.; Javier, N.; Singh, A.; Chen, H.; Manzanillo, P.; Lo, M.C.; Huang, X.
Structures and mechanism of human glycosyltransferase beta1,3-N-acetylglucosaminyltransferase 2 (B3GNT2), an important player in immune homeostasis
J. Biol. Chem.
296
100042
2021
Homo sapiens (Q9NY97)
brenda
Jackson, J.J.; Siegmund, A.C.; Bai, W.J.; Reed, A.B.; Birkholz, A.B.; Campuzano, I.D.G.; Crequer-Grandhomme, A.; Hu, R.; Modak, R.V.; Sudom, A.; Javier, N.; Sanders, C.; Lo, M.C.; Xie, F.; Cee, V.J.; Manzanillo, P.; Allen, J.G.
Imidazolone as an amide bioisostere in the development of beta-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) inhibitors
J. Med. Chem.
66
16120-16140
2023
Homo sapiens (Q9NY97), Homo sapiens (Q9C0J1)
brenda
EXTERNAL LINKS (specific for EC-Number 2.4.1.149)
html completed
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2026.1 (March 2026)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
![DSMZ Digital Diversity]()
![Global Core Biodata Resource]()
![ELIXIR Core Data Resource]()
![German Network for Bioinformatics Infrastructure]()
